Prostatic angiogenic responses in late life: Antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model

Prostate

Volumn 75, Issue 5, 2015, Pages 484-499

  Montico, Fabio ^a   Kido, Larissa Akemi ^a   Hetzl, Amanda Cia ^a   Cagnon, Valéria Helena Alves ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOHEXANE DERIVATIVE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FINASTERIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLE DERIVATIVE; O-(CHLOROACETYLCARBAMOYL)FUMAGILLOL; PYRROLE DERIVATIVE; SEMAXANIB; SESQUITERPENE; STEROID 5ALPHA REDUCTASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ADENOCARCINOMA; ANIMAL; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE; TUMOR MICROENVIRONMENT; VASCULARIZATION; WESTERN BLOTTING;

5-ALPHA REDUCTASE INHIBITORS; ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CYCLOHEXANES; DISEASE MODELS, ANIMAL; ENDOSTATINS; FIBROBLAST GROWTH FACTOR 2; FINASTERIDE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PYRROLES; SESQUITERPENES; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85027953729     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22934     Document Type: Article

References (85)

1. Krtolica A, Campisi J. Cancer and aging: a model for the cancer promoting effects of the aging stroma. Int J Biochem Cell Biol 2002; 34(11):1401-1414.
2. Van Moorselaar RJ, Voest EE. Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002; 197(1-2):239-250.
3. Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer 2008; 98-(2):245-249.
4. Sprenger CC, Plymate SR, Reed MJ. Extracellular influences on tumour angiogenesis in the aged host. Br J Cancer 2008; 98(2): 250-255.
5. Mukherji D, Temraz S, Wehbe D., Shamseddine A. Angiogenesis and anti-angiogenic therapy in prostate cancer. Crit Rev Oncol Hematol 2013; 87(2):122-131.
6. Banerjee PP, Banerjee S, Lai J.M., Srandberg JD, Zirkin BR, Brown TR. Age-dependent and lobe-specific spontaneous hyperplasia in the Brown Norway rat prostate. Biol Reprod 1998; 59(5):1163-1170.
7. Banerjee S, Banerjee PP, Brown TR. Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age. Endocrinology 2000; 141(2):821-832.
8. Banerjee PP, Banerjee S, Brown TR. Increased androgen receptor expression correlates with development of agedependent, lobe-specific spontaneous hyperplasia of the Brown Norway rat prostate. Endocrinology 2001; 142(9):4066-4075.
9. Lau KM, Tam NN, Thompson C, Cheng RY. Leung, YK, Ho SM. Age-associated changes in histology and gene-expression profile in the rat ventral prostate. Lab Invest 2003; 83(5): 743-757.
10. Bianchi-Frias D, Vakar-Lopez F, Coleman I.M., Plymate SR, Reed MJ, Nelson PS. The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS ONE 2010; 5(9):e12501.
11. Montico F, Hetzl AC, Cândido EM, Favaro W.J., Cagnon VHA. Hormonal therapy in the senescence: Prostatic microenvironment structure and adhesion molecules. Micron 2011; 42(6): 642-655.
12. Montico F, Hetzl AC, Cândido EM, Cagnon VH. Angiogenic and tissue remodeling factors in the prostate of elderly rats submitted to hormonal replacement. Anat Rec (Hoboken) 2013; 296(11):1758-1767.
13. Hetzl AC, Montico F, Lorencini R.M., Kido LA, Cândido EM, Cagnon VH. Prostatic microenvironment in senescence: fibroblastic growth factors x hormonal imbalance. Histochem Cell Biol 2014; 141(5):531-542.
14. Montico F, Kido LA, Hetzl A.C., Lorencini RM, Cândido EM, Cagnon VH. Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: A comparative study of prostate disorders in aged and TRAMP mice. Histochem Cell Biol 2014; 42(3):269-284.
15. Erschler WB. Why tumors grow more slowly in old people. J Natl Cancer Inst 1986; 77(4):837-839.
16. Campisi J, Senescent cells. Tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005; 120(4):513-522.
17. Reed MJ, Karres N, Eyman D., Cruz A, Brekken RA, Plymate S. The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. Int J Cancer 2007; 120(4):753-760.
18. Damodarasamy M, Vernon RB, Chan C.K., Plymate SR, Wight TN, Reed MJ. Hyaluronan in aged collagen matrix increases prostate epithelial cell proliferation. In Vitro Cell Dev Biol Anim 2014; [Epub ahead of print].
19. Liekens S, De Clercq E, Neyts J, Angiogenesis:. Regulators and clinical applications. Biochem Pharmacol 2001; 61(3):253-270.
20. Doll JA, Reiher FK, Crawford S.E., Pins MR, Campbell SC, Bouck NP. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001; 49(4):293-305.
21. Reynolds AR, Kyprianou N. Growth factor signalling in prostatic growth: Significance in tumour development and therapeutic targeting. Br J Pharmacol 2006; 147:(Suppl 2): 144 (Suppl 2):S152.
22. Huss WJ, Hanrahan CF, Barrios R.J., Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001; 61(6):2736-2743.
23. Berger AP, Kofler K, Bektic J., Rogatsch H, Steiner H, Bartsch G., Klocker H. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57(1):57-65.
24. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 2006; 13(3):739-749.
25. Macpherson GR, Ng SSW, Forbes SL, Melillo G, Karpova T., McNally J, Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, Figg WD. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther 2003; 2(9):845-854.
26. Mabjeesh NJ, Amir S. Hypoxia-inducible factor (HIF) in human tumorigenesis. Histol Histopathol 2007; 22(5):559-572.
27. Kwabbi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004; 11(4):709-724.
28. Folkman JHP, Hlatky L. The logic of anti-angiogenic gene therapy. In: Friedmann T, editor. The development of gene therapy. New York: Cold Spring Harbor Laboratory Press; 1998. pp. 1-17.
29. Retter AS, Figg WD, Dahut WL. The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. Clin Prostate Cancer 2003; 2(3):153-159.
30. Fong TA, Shawver LK, Sun L, Tang C., App H, Powell TJ, Kim Y.H., Schreck R., Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59(1): 99-106.
31. O'Reilly MS, Boehm T, Shing Y., Fukai N, Vasios G, Lane W.S., Flynn E., Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2):277-285.
32. Matsusaka S, Nakasho K, Terada N., Sugihara A, Tsujimura T, Takanashi T., Uematsu K, Okamoto E, Toyosaka A. Inhibition by an angiogenesis inhibitor, TNP-470, of the growth of a human hepatoblastoma heterotransplanted into nude mice. J Pediatr Surg 2000; 35(8):1198-1204.
33. Sin N, Meng L, Wang M.Q., Wen JJ, Bornmann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase. MetAP-2. Proc Natl Acad Sci USA 1997; 94(12):6099-6103.
34. Castronovo V, Belotti D. TNP-470 (AGM-1470): Mechanisms of action and early clinical development. Eur J Cancer 1996; 32A-(14):2520-2527.
35. Turk BE, Griffith EC, Wolf S, Biemann K., Chang YH, Liu JO. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999; 6(11):823-833.
36. Figg WD, Kruger EA, Price D.K., Kim S., Dahut WD. Inhibition of angiogenesis: Treatment options for patients with metastatic prostate cancer. Invest New Drugs 2002; 20(2):183-194.
37. Franck-Lissbrant I, Haggstrom S, Damber J.E., Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139-(2):451-456.
38. Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostate hyperplasia: long-term follow-up. Urology 1998; 51(2):237-240.
39. Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int 2000; 85(1):70-73.
40. Greenberg NM, Demayo F, Finegold M.J., Medina D., Tilley WD, Aspinall JO, Cunha GR, Donjacour A.A., Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92(8):3439-3443.
41. Gingrich JR, Barrios RJ, Foster B.A., Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999; 2(2):70-75.
42. Strieth S, Eichhorn ME, Sutter A, Jonczyk A., Berghaus A, Dellian M. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 2006; 119(2):423-431.
43. Gonzales GF, Gasco M, Malheiros-Pereira A, Gonzales-Castañeda C. Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice. Andrologia 2008; 40(3):179-185.
44. Tutrone RF Jr, Ball RA, Ornitz D.M., Leder P., Richie JP Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model. J Urol 1993; 149(3):633-699.
45. Tuxhorn JA, Ayala GE, Smith M.J., Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002; (9):2912-2923.
46. Weidner N, Carroll PR, Flax J, Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143(2):401-409.
47. Hochberg DA, Basillote JB, Armenakas N.A., Vasovic L., Shevchuk M, Pareek G, Fracchia JA. Decreased suburethral Prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign Prostatic hyperplasia. J Urol 2002; 167(4):1731-1733.
48. Montgomery DC. Design and Analysis of Experiments, 3rd edition. New York: Wiley; 1991.
49. Zar JH, Biostatistical Analysis, 4th edition. New Jersey: Prentice Hall; 1999.
50. Rivard A, Fabre J, Silver M., Chen D, Murohara T, Kearney M., Magner M, Ashara T, Isner JM. Aged-dependent impairment of angiogenesis. Circulation 1999; 99(1):111-120.
51. Coppe JP, Kauser K, Campisi J., Beausejour CM. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006; 281(40):29568-29574.
52. Slater M, Barden JA, Murphy CR. Changes in growth factor expression in the ageing prostate may disrupt epithelial-stromal homeostasis. Histochem J 2000; 32(6):357-364.
53. Huss WJ, Barrios RJ, Foster B.A., Greenberg NM. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003; 54(1):8-16.
54. Zhong H, Semenza GL, Simons J.W., De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004; 28(2):88-93.
55. Li Y, Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev 2010; 30(1):23-66.
56. Luo Y, He DL, Ning L, Shen S.L., Li L., Li X, Zhau HE, Chung LW. Over-expression of hypoxia-inducible factor-1alpha increases the invasive potency of LNCaP cells in vitro. BJU Int 2006; 98(6):1315-1319.
57. Gonzalez-Moreno O, Lecanda J, Green J.E., Segura V., Catena R, Serrano D, Calvo A. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 2010; 316(4):554-567.
58. Luo Y, Lan L, Jiang Y.G., Zhao JH, Li MC, Wei NB, Li YH. Epithelial-mesenchymal transition and migration of prostate cancer stem cells is driven by cancer-associated fibroblasts in an HIF-1a/b-catenin-dependent pathway. Mol Cells 2013; 36-(2):138-144.
59. Darrington E, Zhong M, Vo B.H., Khan SA. Vascular endothelial growth factor A, secreted in response to transforming growth factor-b1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells. Asian J Androl 2012; 14-(5):745-751.
60. Chiarugi P, Paoli P, Cirri P. Tumor microenvironment and metabolism in prostate cancer. Semin Oncol 2014; 41(2):267-280.
61. Polnaszek N, Kwabi-Addo B, Peterson L.E., Ozen M., Greenberg NM, Ortega S, Basilico C, Ittmann M. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003; 63(18):5754-5760.
62. Huss WJ, Barrios RJ, Greenberg NM. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol Cancer Ther 2003; 2(7):611-616.
63. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57-(18):3924-3928.
64. Abdollahi A, Lipson KE, Sckell A, Zieher H., Klenke F, Poerschke D, Roth A., Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003; 63(24):8890-8898.
65. Abe J, Zhou W, Takuwa N., Taguchi J, Kurokawa K, Kumada M., Takuwa Y. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 1994; 54(13):3407-3412.
66. Yoshida A, Anand-Apte B, Zetter BR. Differential endothelial migration and proliferation to basic fibroblast growth factor and vascular endothelial growth factor. Growth Factors 1996; 13(1-2):57-64.
67. Joseph IB, Nelson JB, Denmeade S.R., Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3:2507-2511.
68. Montecinos VP, Godoy A, Hinklin J., Vethanayagam RR, Smith GJ. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PLoS One 2012; 7(1):e29623.
69. Rudolfsson SH, Bergh A. Testosterone-stimulated growth of the rat prostate may be driven by tissue hypoxia and hypoxia-inducible factor-1 alpha. J Endocrinol 2008; 196(1):11-19.
70. Al-Ubaidi FL, Schultz N, Egevad L., Granfors T, Helleday T. Castration therapy of prostate cancer results in downregulation of HIF-1a levels. Int J Radiat Oncol Biol Phys 2012; 82(3):1243-1248.
71. Tuxhorn JA, McAlhany SJ, Yang F, Dang T.D., Rowley DR. Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model. Cancer Res 2002; 62(21):6021-6025.
72. Soulitzis N, Karyotis I, Delakas D., Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGF-β1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006; 29(2):305-314.
73. Das K, Lorena PD, Ng L.K., Lim D., Shen L, Siow WY, Teh M, Reichardt J.K., Salto-Tellez M. Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocr Relat Cancer 2010; 17(3):757-770.
74. Van Meeteren LA, Ten Djike. Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res 2012; 347(1):177-186.
75. Seghezzi G, Patel S, Ren C.J., Gualandris A., Pintucci G, Robbins ES, Shapiro R.L., Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141(7):1659-1673.
76. Song S, Wienties MG, Gan Y. Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 2000; 97(15):8658-8663.
77. Boehm T, Folkman J, Browder T., O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390(6658):404-407.
78. Sim BK, MacDonald NJ, Gubish ER. Angiostatin and endostatin: Endogenous inhibitors of tumor growth. Cancer Metastasis Rev 2000; 19(1-2):181-190.
79. Tilki D, Kilic N, Herbst H., Reich O, Seitz M, Lauke H., Stief CG, Ergün S. High level of endostatin in epididymal epithelium: Protection against primary malignancies in this organ. Histochem Cell Biol 2008; 130(3):527-535.
80. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312(5): 594-607.
81. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001; 166(6):2472-2483.
82. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70(9-10): 561-573.
83. Isayeva T, Chanda D, Kallman L., Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 2007; 67(12):5789-5797.
84. Isayeva T, Moore LD, Chanda D, Chen D., Ponnazhagan S. Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status. Prostate 2009; 69(10):1055-1066.
85. Horti J, Dixon SC, Logothetis C.J., Guo Y., Reed E, Figg WD. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer 1999; 79(9-10):1588-1593.